Acromegaly Medical Services in China

Acromegaly is a rare, chronic endocrine disorder characterized by excessive production of growth hormone (GH), most commonly due to a benign pituitary adenoma. This hormonal overproduction leads to progressive, disfiguring somatic changes—including enlargement of hands, feet, and facial features—as well as systemic complications affecting the cardiovascular, respiratory, metabolic, and musculoskeletal systems. Pathogenesis centers on GH hypersecretion, which stimulates hepatic synthesis of insulin-like growth factor-1 (IGF-1); persistently elevated IGF-1 drives abnormal tissue growth and organ dysfunction. While most cases (over 95%) arise from pituitary somatotroph adenomas, ectopic GH or GHRH secretion (e.g., from bronchial carcinoids or pancreatic tumors) accounts for <1% of cases. Epidemiologically, acromegaly has an estimated prevalence of 40–130 cases per million population and an annual incidence of 3–4 new cases per million. It typically manifests in middle age (mean diagnosis age: 40–45 years), with no significant sex predilection. Delayed diagnosis is common—often taking 5–10 years from symptom onset—due to insidious progression and nonspecific early signs such as fatigue, joint pain, headaches, and gradual facial coarsening. Key risk factors include genetic syndromes like multiple endocrine neoplasia type 1 (MEN1), familial isolated pituitary adenoma (FIPA), and, rarely, Carney complex or McCune-Albright syndrome. Uncontrolled disease significantly impairs quality of life: patients report high rates of depression, anxiety, sleep apnea-related daytime somnolence, reduced physical mobility, sexual dysfunction, and social stigma linked to facial disfigurement. Comorbidities—including hypertension (30–50%), type 2 diabetes (15–30%), obstructive sleep apnea (60–80%), cardiomegaly, and increased colorectal polyp risk—further diminish functional status and contribute to a 2–3-fold higher standardized mortality ratio compared to the general population. Early recognition, multidisciplinary management (endocrinology, neurosurgery, radiology, ophthalmology), and lifelong surveillance are essential to mitigate morbidity and normalize life expectancy.

Acromegaly is a rare, chronic endocrine disorder caused by excessive secretion of growth hormone (GH), most commonly due to a benign somatotroph adenoma of the anterior pituitary gland. Sustained GH hypersecretion leads to elevated insulin-like growth factor-1 (IGF-1) levels, resulting in progressive somatic overgrowth, organomegaly, metabolic dysfunction, and increased morbidity and mortality if left untreated. Management requires a multidisciplinary approach coordinated by endocrinologists, neurosurgeons, radiation oncologists, and allied health professionals. The primary therapeutic goals are normalization of GH and IGF-1 concentrations, tumor volume reduction or stabilization, alleviation of symptoms (e.g., headache, visual field defects, arthralgia, sleep apnea), prevention of complications (e.g., hypertension, diabetes mellitus, cardiomyopathy, colon polyps), and improvement in quality of life.

Conservative treatment forms the cornerstone of long-term management but is rarely sufficient as monotherapy. It includes rigorous monitoring of biochemical parameters (fasting GH, IGF-1, oral glucose tolerance test [OGTT] with GH suppression), serial pituitary MRI for tumor surveillance, and proactive management of comorbidities. Patients require annual cardiovascular risk assessment—including echocardiography, ECG, and ambulatory blood pressure monitoring—as acromegaly confers a two- to threefold increased risk of heart failure and arrhythmias. Sleep apnea screening via polysomnography is mandatory; continuous positive airway pressure (CPAP) therapy is initiated promptly when indicated. Orthopedic evaluation addresses joint degeneration and spinal stenosis, while ophthalmologic assessment monitors for chiasmal compression. Lifestyle interventions—structured weight management, low-glycemic-index nutrition, regular aerobic and resistance exercise—are evidence-based adjuncts that improve insulin sensitivity and reduce cardiovascular strain.

Pharmacotherapy is employed across all stages: as first-line therapy in patients unfit for surgery (e.g., advanced age, severe comorbidities), as preoperative neoadjuvant treatment to shrink large invasive macroadenomas (>4 cm) and improve surgical outcomes, or as adjuvant therapy following incomplete resection or radiation. Three major drug classes are used: somatostatin receptor ligands (SRLs), dopamine agonists, and GH receptor antagonists. First-generation SRLs—octreotide LAR and lanreotide autogel—are first-line medical therapies, achieving biochemical control (GH <1.0 µg/L and normalized IGF-1) in ~50–60% of patients. They act via high-affinity binding to somatostatin receptor subtype 2 (SSTR2) on tumor cells, inhibiting GH secretion and exerting antiproliferative effects. Pasireotide, a multireceptor-targeted SRL with affinity for SSTR1,2,3,5, demonstrates superior efficacy in some octreotide-resistant cases but carries higher risks of hyperglycemia. Cabergoline, a potent dopamine D2 receptor agonist, achieves biochemical control in ~20–30% of patients, particularly those with mixed GH/prolactin-secreting tumors; it is often used as add-on therapy. Pegvisomant, a recombinant GH receptor antagonist, normalizes IGF-1 in >90% of patients regardless of tumor size or prior treatment history, but does not suppress GH secretion or reduce tumor volume—thus requiring concurrent imaging surveillance. Its use necessitates monthly liver enzyme monitoring due to rare hepatotoxicity.

Surgical treatment remains the initial intervention of choice for most patients with newly diagnosed acromegaly, especially those with microadenomas (<1 cm) or non-invasive macroadenomas. Transsphenoidal surgery (TSS), performed via endoscopic or microscopic approaches, offers the highest probability of immediate biochemical remission—achieving cure rates of 70–90% for microadenomas and 40–60% for macroadenomas. Advantages include rapid symptom relief (e.g., headache resolution within days), immediate GH/IGF-1 decline, avoidance of long-term medication side effects, and definitive histopathological diagnosis. In experienced centers, complication rates are low: permanent diabetes insipidus occurs in <2%, CSF leak in <3%, and new anterior pituitary hormone deficiencies in 5–10%. Postoperative remission is confirmed by measuring random GH <0.4 µg/L and normal IGF-1 at least 12 weeks after surgery, following resolution of the acute stress response.

Radiation therapy—including conventional fractionated radiotherapy, stereotactic radiosurgery (e.g., Gamma Knife, CyberKnife), and proton beam therapy—is reserved for persistent or recurrent disease refractory to surgery and medical therapy. While effective in controlling tumor growth in >95% of cases, biochemical remission is delayed (median time 5–10 years), and hypopituitarism develops in 50–80% of patients within 10 years. Therefore, radiation is considered a tertiary modality, not a substitute for timely surgical intervention.

Treatment in China offers distinct advantages rooted in infrastructure, expertise, and integration. Major academic hospitals—such as Peking Union Medical College Hospital, Shanghai Ruijin Hospital, and West China Hospital—host nationally accredited Pituitary Centers of Excellence with dedicated neuroendocrine teams performing >200 transsphenoidal surgeries annually. Endoscopic endonasal approaches are standard, with intraoperative MRI and neuronavigation enhancing precision and safety. China’s National Medical Insurance Program now covers first-line SRLs (lanreotide, octreotide LAR) and pegvisomant, significantly improving accessibility. Moreover, domestic biosimilar development has reduced costs without compromising efficacy or safety profiles. Multidisciplinary Acromegaly Clinics provide integrated care—coordinating endocrinology, neurosurgery, ophthalmology, cardiology, and rehabilitation—ensuring standardized follow-up per Chinese Acromegaly Consensus Guidelines (2023). Telemedicine platforms facilitate rural patient access to specialist review and remote IGF-1 monitoring, mitigating geographic disparities.

Recovery advice emphasizes structured, lifelong engagement. Patients should attend scheduled endocrinology visits every 3–6 months initially, then annually if stable. Biochemical monitoring must continue indefinitely—even after apparent cure—to detect late recurrence (risk ~2–5% per year). Hormone replacement (e.g., hydrocortisone, levothyroxine, testosterone/estradiol) must be titrated carefully under supervision, with stress-dose glucocorticoids prescribed for intercurrent illness or surgery. Patients are advised to avoid smoking, limit alcohol, maintain BMI <24 kg/m², and engage in supervised physical activity to preserve musculoskeletal integrity. Psychological support is integral: depression and anxiety prevalence exceeds 30% in acromegaly, warranting routine screening and cognitive-behavioral therapy referral when indicated. Finally, patients should receive age- and sex-appropriate cancer screening—particularly colonoscopy starting at diagnosis (due to increased colorectal neoplasia risk) and thyroid ultrasound—underscoring that acromegaly management extends far beyond hormonal normalization to holistic, preventive, person-centered care.